X4 Pharmaceuticals, Inc. (XFOR) Stock Overview
Explore X4 Pharmaceuticals, Inc.’s financial performance, market position, analyst ratings, and future outlook.
X4 Pharmaceuticals, Inc. (XFOR)
Key Financials
Key Financials
Market Cap
371.6M
P/E Ratio
-0.87
EPS (TTM)
$-4.54
ROE
-0.95%
XFOR Stock Analysis & Investment Overview (NASDAQ)
Our AI-powered analysis of X4 Pharmaceuticals, Inc. (NASDAQ: XFOR) gives investors deep insight into how the stock performs on the NASDAQ exchange, its growth potential, and its market positioning. With a Meyka AI Score of B, X4 Pharmaceuticals, Inc.'s NASDAQ-listed shares demonstrate moderate investment characteristics based on our machine learning models.
The current technical analysis of XFOR on the NASDAQ shows an RSI of 50.19, suggesting the stock is in a a neutral condition. Our forecasting models predict a 12-month price target of $5.31 for the NASDAQ listing.
Key metrics behind X4 Pharmaceuticals, Inc.'s NASDAQ-traded stock include a P/E ratio of -0.87 and a market capitalization of 371.6M. Combined with our AI analysis, these give both institutional and retail investors a clear view of XFOR on the NASDAQ.